by James Rudge, PhD, Technical Director, Neoteryx | 6 min read
An article by Marieke Zijlstra et al at Sanguin in the Netherlands published in the January 2021 issue of the Journal of Pediatric Gastroenterology and Nutrition reports on a pilot …
Read Storyby James Rudge, PhD, Technical Director, Neoteryx | 6 min read
An article by David J Marshall and Brian G Keevil et al at Wythenshawe Hospital and Nottingham Hospital, UK that was published in the July 2020 issue of Annals of …
Read Storyby James Rudge, PhD, Technical Director, Neoteryx | 8 min read
An article published by Nils T. Vethe et al in the October 2019 issue of Therapeutic Drug Monitoring, reported on the successful validation of 10 µL Mitra® devices from 26-27 …
Read Storyby Neoteryx | 2 min read
Methadone is one of the medications approved by the US Food and Drug Administration (FDA) for use in the treatment of Opioid Use Disorder (OUD). It is a long-acting opioid …
Read Storyby Neoteryx | 3 min read
Kang and Lee define TDM (therapeutic drug monitoring) as a clinical laboratory measurement of a particular drug in a patient’s bloodstream that, with proper medical interpretation and optimized and individualized …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.